Targeting genetic changes in lung adenocarcinoma
Official title: Lung Adenocarcinoma: From Genome Alterations to Therapeutic Discovery
Funded at Dana-Farber Cancer Inst · NIH-11131217 · Data updated 2026-11-12
Looking at genetic changes in lung adenocarcinoma to find new targeted treatments for people with this cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | August 1, 2015 |
| Project end | July 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $1,044,600 |
| NIH project number | 5R35CA197568-12 |
| Project ID | NIH-11131217 on NIH RePORTER |
Who could benefit from this research
✓Could help
People diagnosed with lung adenocarcinoma—especially those having their tumor genetically sequenced or with recurrent/metastatic disease—are the most relevant candidates for related clinical opportunities.
✕Less likely to help
People without lung adenocarcinoma or whose tumors lack relevant genetic alterations may not directly benefit from this research.
What this research studies
Researchers analyze the DNA of lung adenocarcinoma tumors from patients to find the mutations that drive the cancer. They follow up key findings in the lab using cellular and animal models to understand how specific genes (like BRAF, EGFR, SOS1, MGA, and ADAR) or duplicated regulatory elements promote tumor growth. The team also builds genomically engineered models of aneuploidy to mimic patient tumors and test potential therapeutic approaches. Results aim to improve diagnostic markers and point to drug targets that could be tested in future clinical trials.
Why it matters
Potential benefit: If successful, this work could lead to more precise treatments matched to the genetic patterns in a patient's tumor.
How similar studies have gone: Prior genomic discoveries such as EGFR and BRAF mutations have successfully led to targeted therapies, and this work builds on those proven approaches.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Meyerson, Matthew L. — Dana-Farber Cancer Inst
- Study coordinator: Meyerson, Matthew L.
Related research
Other NIH-funded projects on the same topics.
-
Understanding a highly flexible cell state in lung cancer that worsens outcomes
A doctor-scientist at Cedars-Sinai wants to learn how a highly adaptable lung cancer cell state drives disease progression and resistance to therapy, using models that resemble human tumors.
-
Breaking cytokine loops in LKB1-mutant lung cancer and the immune system
A researcher at NYU School of Medicine is studying why a common lung cancer subtype with a specific mutation doesn’t respond well to current immunotherapy, with the aim of finding new ways to improve treatment.
-
Lung Adenocarcinoma: From Genome Changes to New Therapies
This NIH grant supports research on lung adenocarcinoma to better understand its genome changes and translate that knowledge into better diagnosis and treatments for patients.
-
Understanding how lung cancer and immune cells influence each other in early lung cancer development
A study looks at how lung cells and immune cells change together as early lung cancer (lung adenocarcinoma) develops, with the goal of finding points to intervene early.
-
Targeting a cancer pathway to stop metastasis in SMARCA4-deficient lung cancer
This grant aims to understand and interrupt a key pathway that drives spread of a specific type of lung cancer in people whose tumors have SMARCA4 mutations.
-
Combining imaging and biopsy genes to spot aggressive vs. slow-growing early lung cancer before surgery
Aimed at people with early-stage lung adenocarcinoma, this project tests a combined imaging and biopsy gene‑marker approach to better predict tumor aggressiveness before surgery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.